文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

血清microRNA-92a和microRNA-146a水平联合肺超声评分预测急性呼吸窘迫综合征严重程度和预后的价值

[The value of serum microRNA-92a and microRNA-146a levels combined with pulmonary ultrasound score in predicting the severity and prognosis of acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论ARDS患者入院时血清miR-92a、miR-146a联合LUS评分可预测28天死亡,联合AUC 0.918,高于单项指标。

该研究纳入116例ARDS患者,入院当天检测血清miR-92a、miR-146a(RT-PCR)并行12区域肺超声计算LUS评分。死亡组三项指标均显著高于存活组,且随ARDS严重程度加重而升高。多因素Logistic回归显示低OI、高LUS评分、高miR-92a、高miR-146a为死亡独立危险因素。三者联合预测死亡的AUC 0.918,显著高于单项(0.842、0.825、0.807),灵敏度94.0%、特异度85.2%。

要点

  • 死亡组miR-92a 3.75±1.64 vs 2.10±0.78、miR-146a 1.93±0.72 vs 0.76±0.20、LUS 25.80±4.75 vs 13.40±3.60,均P<0.01。
  • 三项指标随ARDS严重程度加重逐渐升高(F=8.115、6.740、6.216,均P<0.01),重度组显著高于中、轻度组。
  • 多因素回归:低OI(OR=2.748,95%CI 1.913-6.225)、高LUS(OR=1.685,95%CI 1.183-2.758)、高miR-92a(OR=2.560,95%CI 1.806-5.627)、高miR-146a(OR=1.984,95%CI 1.375-3.816)为死亡独立危险因素。
  • 三者联合预测死亡AUC 0.918,高于miR-92a 0.842、miR-146a 0.825、LUS 0.807(均P<0.01),灵敏度94.0%、特异度85.2%。
  • 入院当天即可完成血清miR检测与12区域肺超声LUS评分,联合评估有助于早期识别高危ARDS患者。

适用人群与场景

  • 2017年1月至2020年3月儋州市人民医院收治的ARDS患者116例,入院当天检测。
  • 按28天预后分死亡组39例、存活组77例;按 severity 分轻度20例(200 mmHg<OI≤300 mmHg)、中度38例(100 mmHg<OI≤200 mmHg)、重度58例(OI≤100 mmHg)。

诊断标准与关键阈值

  • ARDS严重程度按氧合指数(OI)分层:轻度200 mmHg<OI≤300 mmHg,中度100 mmHg<OI≤200 mmHg,重度OI≤100 mmHg(1 mmHg=0.133 kPa)。
  • 肺超声检查12个肺区域,总分即LUS评分。
  • 血清miR-92a、miR-146a采用实时荧光定量RT-PCR检测,以2-ΔΔCt表示表达水平。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 单中心回顾性纳入116例ARDS患者,入院当天检测血清miR-92a、miR-146a并行12区域肺超声LUS评分。
  • 死亡组miR-92a(2-ΔΔCt)3.75±1.64 vs 存活组2.10±0.78,miR-146a 1.93±0.72 vs 0.76±0.20,LUS 25.80±4.75 vs 13.40±3.60,均P<0.01。
  • 随ARDS加重三项指标逐渐升高(F=8.115、6.740、6.216,均P<0.01);重度组miR-92a 3.65±1.62 vs 中度2.87±1.16、轻度1.94±0.68,miR-146a 1.85±0.58 vs 1.30±0.51、0.68±0.17,LUS 24.15±4.65 vs 18.60±4.20、12.20±3.15,均P<0.01。
  • 多因素Logistic回归:低OI(OR=2.748,95%CI 1.913-6.225,P=0.024)、高LUS(OR=1.685,95%CI 1.183-2.758,P=0.016)、高miR-92a(OR=2.560,95%CI 1.806-5.627,P<0.001)、高miR-146a(OR=1.984,95%CI 1.375-3.816,P=0.008)为死亡独立危险因素。
  • ROC:三者联合预测死亡AUC 0.918,高于miR-92a 0.842、miR-146a 0.825、LUS 0.807(均P<0.01),灵敏度94.0%、特异度85.2%。

证据类型、等级与局限

  • 单中心回顾性研究,样本量116例,未提及盲法与样本量估算,原文未给出证据等级或推荐强度。
  • 联合预测的AUC、灵敏度、特异度来自ROC曲线分析,尚未经前瞻性外部验证。

对床旁实践的改变

  • 对入院ARDS患者,除OI和LUS外,可考虑加测血清miR-92a、miR-146a,三者联合用于28天死亡风险分层(联合AUC 0.918)。
  • 单项指标预测价值低于联合(AUC 0.807-0.842),不宜单独据此决定治疗强度。
  • 该研究为单中心回顾性,联合模型的阈值与决策效用尚未在前瞻性队列中验证,不能替代现有病情评估。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the value of serum microRNA-92a (miR-92a) and microRNA-146a (miR-146a) expression levels combined with lung ultrasound score (LUS) in predicting the severity and prognosis of acute respiratory distress syndrome (ARDS).

METHODS: 116 patients with ARDS admitted to Danzhou People's Hospital from January 2017 to March 2020 were enrolled. On the day of admission, the expression levels of serum miR-92a and miR-146a were detected by real-time fluorescent quantitative reverse transcript-polymerase chain reaction (RT-PCR), and pulmonary ultrasound examination was performed in 12 lung regions, with the total score as LUS score. The difference of each index was analyzed among the ARDS patients with different 28-day prognosis (survival group and death group) and different severity [mild group: 200 mmHg < oxygenation index (OI) ≤ 300 mmHg (1 mmHg = 0.133 kPa), moderate group: 100 mmHg < OI ≤ 200 mmHg, severe group: OI ≤ 100 mmHg]. Multivariate Logistic regression was used to analyze the risk factors of death in patients with ARDS. Receiver operating characteristic (ROC) curve was drawn to analyze the value of miR-92a and miR-146a combined with LUS score in predicting the death of patients with ARDS.

RESULTS: 116 ARDS patients were included, 39 cases in the death group, 77 cases in the survival group; 20 cases in the mild group, 38 cases in the moderate group and 58 cases in the severe group. The expression levels of serum miR-92a, miR-146a and LUS score in the death group were significantly higher than those in the survival group [miR-92a (2-ΔΔCt): 3.75±1.64 vs. 2.10±0.78, miR-146a (2-ΔΔCt): 1.93±0.72 vs. 0.76±0.20,LUS score: 25.80±4.75 vs. 13.40±3.60, all P < 0.01]. With the aggravation of ARDS patients, the expression levels of serum miR-92a and miR-146a and LUS score gradually increased (F values were 8.115, 6.740 and 6.216 respectively, all P < 0.01). The expression levels of serum miR-92a, miR-146a and LUS score in severe group were significantly higher than those in the moderate group and mild group [miR-92a (2-ΔΔCt): 3.65±1.62 vs. 2.87±1.16, 1.94±0.68; miR-146a (2-ΔΔCt): 1.85±0.58 vs. 1.30±0.51, 0.68±0.17; LUS score: 24.15±4.65 vs. 18.60±4.20, 12.20±3.15, all P < 0.01]. Multivariate Logistic regression analysis showed that low OI [odds ratio (OR) = 2.748, 95% confidence interval (95%CI) was 1.913-6.225, P = 0.024], high LUS score (OR = 1.685, 95%CI was 1.183-2.758, P = 0.016), high expression levels of serum miR-92a (OR = 2.560, 95%CI was 1.806-5.627, P < 0.001) and miR-146a (OR = 1.984, 95%CI was 1.375-3.816, P = 0.008) were independent risk factors for the death of ARDS patients. ROC curve analysis showed that the area under ROC curve (AUC) of patients with ARDS predicted by miR-92a and miR-146a combined with LUS score was significantly higher than that predicted by the three alone (0.918 vs. 0.842, 0.825, 0.807, all P < 0.01), and the sensitivity (94.0%) and specificity (85.2%) were higher.

CONCLUSIONS: The expression levels of serum miR-92a, miR-146a and LUS score are related to the severity and prognosis of the patients with ARDS, and the combination of the three indicators has better value in predicting the prognosis of the patients with ARDS.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yu Y, Liu Z, Liao H, et al. [The value of serum microRNA-92a and microRNA-146a levels combined with pulmonary ultrasound score in predicting the severity and prognosis of acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33198870. doi:10.3760/cma.j.cn121430-20200409-00268

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。